Mercury Pharmaceuticals

Researchers identify the limiting factors behind protein diversification

The number of known proteins is infinitely small in comparison to the universe of possible proteins which could in theory be realized.

Strategic Partnerships at PHARMAP 2026 – Big Pharma’s Shift Toward CDMOs and CMOs

Mirror image proteins offer new way to disable Alzheimer's disease

Understanding how proteins interact with their own mirror images enabled a Kobe University research team to design a small mirror protein that disables a causal factor of Alzheimer's disease, amyloid-beta.

How swapping unhealthy foods can significantly reduce your heart risk

More than half of adults and about 60% of children in the U.S. have unhealthy diets, which can contribute to higher rates of health factors such as high blood pressure and obesity, and lead directly to poor health outcomes including deaths from cardiovascular disease and other chronic conditions, according to the American Heart Association.

Excessive RNA editing enzyme alters brain circuit formation in Down syndrome

A collaborative research study co-led by scientists at the Icahn School of Medicine at Mount Sinai and the Liber Institute for Brain Development has for the first time identified a biological process that may help explain how the brain develops differently in people with Down syndrome.

Scientists use living muscle to reanimate paralyzed organs

What if a technology could reanimate parts of the body that have lost their connection to the brain - like a bladder that can no longer empty due to a spinal cord injury, or intestines that can't push food forward due to Crohn's disease? What if this technology could also send sensations such as hunger or touch back to the brain?

Lifestyle care in primary clinics allows for safe diabetes deprescribing

A new research study provides real-world evidence that deprescribing glucose‑lowering medications is both feasible and safe when patients with type 2 diabetes receive lifestyle‑informed care in primary care settings.

Semarion secures $3.8 million to scale next-generation cell assay technology and accelerate pharma adoption

Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, today announced it has raised $3.8 million USD (£2.9 million GBP).

Broken String Biosciences rebrands to reflect strategic evolution as demand grows for unbiased genome-wide off-target analysis

Broken String Biosciences, a biotechnology company enabling gene editing teams to accelerate development of safer, more effective genetic medicines, today introduced new branding and comprehensive website as part of its strategic repositioning.

Trump’s hunt for undocumented Medicaid enrollees yields few violators

Last August, as part of the federal government's crackdown on people in the country illegally, the Trump administration sent states the names of hundreds of thousands of Medicaid enrollees with orders to determine whether they were ineligible based on immigration status.